Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.
Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 micrograms/ml in a short time. Plasma steady-state levels of 4-10 micrograms/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6 +/- 1.1 h and 0.78 +/- 0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4'-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.
D000818:Animals; D004334:Drug Administration Schedule; D005260:Female; D007275:Injections, Intravenous; D007700:Kinetics; D008657:Metabolic Clearance Rate; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000008:administration & dosage* / Q000378:metabolism / Q000652:urine
D013713:Teniposide; D011034:Podophyllotoxin